These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34922745)

  • 21. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
    da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era.
    Kazami Y; Oba A; Ono Y; Sato T; Inoue Y; Saiura A; Takahashi Y; Ito H
    HPB (Oxford); 2023 Oct; 25(10):1169-1178. PubMed ID: 37357111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.
    Zakem SJ; Mueller AC; Meguid C; Torphy RJ; Holt DE; Schefter T; Messersmith WA; McCarter MD; Del Chiaro M; Schulick RD; Goodman KA
    HPB (Oxford); 2021 Jul; 23(7):1072-1083. PubMed ID: 33277184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis.
    Xue K; Huang X; Zhao P; Zhang Y; Tian B
    Int J Surg; 2023 Dec; 109(12):4309-4321. PubMed ID: 38259002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
    Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
    Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.
    Yamada S; Hashimoto D; Yamamoto T; Yamaki S; Oshima K; Murotani K; Sekimoto M; Nakao A; Satoi S
    Pancreatology; 2024 Jun; 24(4):592-599. PubMed ID: 38548551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.
    Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
    Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy.
    Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Todaka A; Fukutomi A; Uesaka K
    Pancreatology; 2021 Dec; 21(8):1451-1459. PubMed ID: 34462214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion.
    Kubo H; Ohgi K; Sugiura T; Ashida R; Yamada M; Otsuka S; Yamazaki K; Todaka A; Sasaki K; Uesaka K
    Ann Surg Oncol; 2022 Aug; 29(8):4992-5002. PubMed ID: 35368218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis.
    Bradley A; Van Der Meer R
    PLoS One; 2019; 14(2):e0212805. PubMed ID: 30817807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer.
    Aoki S; Mizuma M; Hayashi H; Yoshimachi S; Hata T; Miura T; Takadate T; Maeda S; Ariake K; Kawaguchi K; Masuda K; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Motoi F; Unno M
    Pancreatology; 2020 Dec; 20(8):1711-1717. PubMed ID: 33032923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.